文献速递心脑血管急症

利伐沙班用于风湿性心脏病相关心房颤动

Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation.
PubMed 文献 · N Engl J Med · 2022-08-28
一句话结论风湿性心脏病相关房颤患者中,维生素K拮抗剂较利伐沙班降低心血管事件或死亡复合终点,且不增加出血。

INVICTUS试验纳入4565例风湿性心脏病相关心房颤动患者,随机接受标准剂量利伐沙班或剂量调整维生素K拮抗剂。最终分析4531例,平均年龄50.5岁,72.3%为女性。意向性治疗分析中,利伐沙班组560例、维生素K拮抗剂组446例发生主要疗效终点事件;限制性平均生存时间利伐沙班组1599天 vs 维生素K拮抗剂组1675天(差值-76天;95%CI -121至-31;P<0.001)。利伐沙班组死亡发生率更高(限制性平均生存时间1608天 vs 1680天;差值-72天;95%CI -117至-28)。两组大出血发生率无显著差异。

要点

  • 风湿性心脏病相关房颤患者中,维生素K拮抗剂组主要复合终点事件446例,少于利伐沙班组560例。
  • 限制性平均生存时间利伐沙班组1599天 vs 维生素K拮抗剂组1675天,差值-76天(95%CI -121至-31;P<0.001)。
  • 利伐沙班组死亡更多:限制性平均生存时间1608天 vs 1680天,差值-72天(95%CI -117至-28)。
  • 两组大出血(ISTH标准)发生率无显著差异。
  • 利伐沙班组永久停药在所有访视点均更常见。

适用人群与场景

  • 心房颤动且超声心动图证实风湿性心脏病,并符合以下任一条件:CHA2DS2VASc评分至少2分(0-9分,评分越高卒中风险越高)、二尖瓣面积不超过2 cm2、左心房自发回声 contrast、左心房血栓。

诊断标准与关键阈值

  • 入选标准包括CHA2DS2VASc评分至少2分(0-9分,评分越高卒中风险越高)、二尖瓣面积不超过2 cm2、左心房自发回声对比或左心房血栓。

处置流程与药物剂量

  • 随机接受标准剂量利伐沙班或剂量调整维生素K拮抗剂治疗。

研究设计与关键结果

  • INVICTUS试验为随机对照试验,纳入4565例患者,最终分析4531例,平均年龄50.5岁,72.3%为女性。
  • 主要疗效终点为卒中、系统性栓塞、心肌梗死或血管性(心源性或非心源性)或不明原因死亡的复合终点。
  • 意向性治疗分析中,利伐沙班组560例、维生素K拮抗剂组446例发生主要终点事件;生存曲线非比例。
  • 限制性平均生存时间利伐沙班组1599天 vs 维生素K拮抗剂组1675天,差值-76天(95%CI -121至-31;P<0.001)。
  • 死亡发生率利伐沙班组高于维生素K拮抗剂组:限制性平均生存时间1608天 vs 1680天,差值-72天(95%CI -117至-28)。
  • 主要安全终点大出血(国际血栓与止血学会标准)两组发生率无显著差异。
  • 利伐沙班组试验药物永久停药在所有访视点均较维生素K拮抗剂组更常见。

证据类型、等级与局限

  • 证据类型:随机对照试验(INVICTUS,NCT02832544,由拜耳资助)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在风湿性心脏病相关房颤患者中,维生素K拮抗剂治疗较利伐沙班降低心血管事件或死亡复合终点发生率,且不增加出血。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation has been limited.

METHODS: We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA2DS2VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), a mitral-valve area of no more than 2 cm2, left atrial spontaneous echo contrast, or left atrial thrombus. Patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or noncardiac) or unknown causes. We hypothesized that rivaroxaban therapy would be noninferior to vitamin K antagonist therapy. The primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis.

RESULTS: Of 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, -76 days; 95% confidence interval [CI], -121 to -31; P<0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, -72 days; 95% CI, -117 to -28). No significant between-group difference in the rate of major bleeding was noted.

CONCLUSIONS: Among patients with rheumatic heart disease-associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022. PMID: 36036525. doi:10.1056/NEJMoa2209051

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。